Chang JS, et al. - In patients with locoregionally confined recurrent or persistent epithelial ovarian cancer, the involved-field radiation therapy (IFRT) was tested in terms of efficacy and safety as a treatment option. Patients received IFRT at a dose of ≥45 Gy for all tumors with 10–15-mm margins as seen on standard imaging. The outcomes of interest were progression-free survival (PFS; primary endpoint) and the safety, response rate, local control, and overall survival (OS). A median follow-up of 28 (range, 17–42) months revealed the median PFS of 7 months and the 2-year PFS rate of 39.3%. Despite failure to meet the primary endpoint, this study suggested that, IFRT might be safe and effective for in-field tumor control in patients with persistent epithelial ovarian cancer with a limited number of metastatic foci.